Immunotherapy delivered by Blinatumomab improves survival in acute lymphoblastic leukaemia patients
Adult patients with acute lymphoblastic leukemia (ALL) can achieve disease control in 90% of cases with intense chemotherapy but only half of these responders will be cured. For patients who are either refractory or relapse after chemotherapy the outcome is dismal despite undergoing more chemotherapy and/or an allogeneic haematopoetic stem cell transplantation. Immunotherapy offers a new treatment option. This can be delivered by the bispecifc antibody construct blinatumomab, which can engage with patients own T cells to fight ALL cells. A single arm Phase II trials with Blinatumomab has shown that 43% of relapsed or refractory (r/r) ALL patients can achieve disease control. The aim of Tower trial was to answer the question if blinatumomab can achieve a survival benefit in adult patients with r/r acute lymphoblastic leukemia compared to standard chemotherapy (SOC). More than 400 r/r ALL patients in Europe, North America, Asia and Australia were randomised 2:1 to receive either blinatumomab or SOC. The trial was stopped prematurely as blinatumomab demonstrated almost doubling of the overall survival when compared to chemotherapy. This benefit was seen in all subgroup of patients including patients who relapsed after an allogeneic haematopoetic stem cell transplantation and/or who have received multiple different chemotherapy regiments. Blinatumomab treatment did not result in more serious side effects than chemotherapy.
In conclusion Blinatumomab is the first immunotherapy agent that has proven to extend patients life with relapsed acute lymphoblastic leukemia when compared to chemotherapy.
Presenter: Dr Max S Topp
Affiliation: Medizinische Klinik II, Universitätsklinikum Würzburg, Germany
Topic: BLINATUMOMAB IMPROVED OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY PHILADELPHIA NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY (TOWER)
Abstract S149 will be presented by Max S Topp on Friday, June 10, 2016, 16:35 - 16:45 in Hall A1.
About the EHA Annual Congress
Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments. The latest data on research and developments will be presented. The topics range from stem cell physiology and development, to leukemia, lymphoma, myeloma - diagnosis and treatment; red blood cells -, white blood cells- and platelet disorders; thrombosis and bleeding disorders.
EHA Executive Office
Ineke van der Beek, Jon Tarifa
Mobile: +31(0)6 2011 1055